Faeth Therapeutics (FTH) Other Non-Current Assets (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Other Non-Current Assets came in at $167000.0 in Q1 2026, up 595.83% YoY from $24000.0 in Q1 2025, and up 827.78% on a QoQ basis from $18000.0 in Q4 2025.
Faeth Therapeutics (FTH) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Other Non-Current Assets data on file, last reported at $167000.0 in Q1 2026.
- Quarterly Other Non-Current Assets rose 595.83% year-over-year to $167000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $167000.0 (up 595.83% YoY) and the FY2025 annual result came in at $18000.0, down 62.5% from the prior year.
- Other Non-Current Assets improved to $167000.0 in Q1 2026, from $18000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $167000.0 in Q1 2026 to a low of $18000.0 in Q3 2025.
- A 5-year average of $64117.6 and a median of $63000.0 in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2025 — Other Non-Current Assets plunged 79.31% — and 2026, when it surged 595.83%.
- Tracing FTH's Other Non-Current Assets over 5 years: stood at $63000.0 in 2022, then jumped by 36.51% to $86000.0 in 2023, then slumped by 44.19% to $48000.0 in 2024, then slumped by 62.5% to $18000.0 in 2025, then jumped by 827.78% to $167000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $167000.0 (Q1 2026), $18000.0 (Q4 2025), and $18000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 62.96 Mn |
| 10 | Faeth Therapeutics | 182.33 Mn | 182.33 Mn | - | 80,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80,000.00 |
| Mar 31, 2026 | 167,000.00 |
| Dec 31, 2025 | 18,000.00 |
| Sep 30, 2025 | 18,000.00 |
| Jun 30, 2025 | 24,000.00 |
| Mar 31, 2025 | 24,000.00 |
| Dec 31, 2024 | 48,000.00 |
| Sep 30, 2024 | 87,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | 86,000.00 |
| Dec 31, 2023 | 86,000.00 |
| Sep 30, 2023 | 86,000.00 |
| Jun 30, 2023 | 86,000.00 |
| Mar 31, 2023 | 81,000.00 |
| Dec 31, 2022 | 63,000.00 |
| Sep 30, 2022 | 45,000.00 |
| Jun 30, 2022 | 45,000.00 |
| Mar 31, 2022 | 39,000.00 |
| Dec 31, 2021 | 39,000.00 |
| Sep 30, 2021 | 27,000.00 |